Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 76.15%: Read This Before Placing a Bet

Core Viewpoint - Beam Therapeutics Inc. (BEAM) has seen a 2.8% increase in share price over the past four weeks, closing at $25.79, with a potential upside of 76.2% based on Wall Street analysts' mean price target of $45.43 [1] Price Targets - The average of 14 short-term price targets ranges from a low of $20.00 to a high of $80.00, with a standard deviation of $18.14, indicating variability among analysts [2] - The lowest estimate suggests a decline of 22.5% from the current price, while the highest estimate indicates a potential upside of 210.2% [2] Analyst Consensus and Earnings Estimates - Analysts show strong agreement in revising earnings estimates higher, which historically correlates with stock price movements [4][11] - Over the last 30 days, one estimate has increased, leading to a 2.9% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank - BEAM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a solid potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]